Male gender (%)
|
81.9
|
Age (years)
|
69.8 (9.1)
|
Body surface area (m2)
|
1.66 (0.19)
|
Body mass index (kg/m2)
|
22.7 (3.4)
|
Smoking history (pack-year)
|
39.0 (20.0–50.0)
|
Smoking history ≥ 10 pack-years (%)
|
92.6
|
Emphysema (%)
|
68.1
|
Blood eosinophil levels (%)
|
5.2 (2.8–8.9)
|
Blood eosinophil counts (/µl)
|
351 (150–538)
|
Eosinophilic component (%)
|
59.6
|
FeNO (ppb)
|
31.5 (19.0–59.0)
|
High FeNO (%)
|
46.8
|
Total IgE levels (IU/ml)
|
406 (119–868)
|
Positive levels for total IgE and/or IgE specific to perennial inhalant antigens (%)
|
79.8
|
Bronchial reversibility (%)
|
19.1
|
FEV1 (l)
|
1.64 (0.67)
|
FEV1 per predicted
| |
Disease severity
| |
Mild (%)
|
28.7
|
Moderate (%)
|
42.6
|
Severe/very severe (%)
|
28.7
|
≥ 1 exacerbation in the previous year (%)
|
42.6
|
Inhaled long-acting bronchodilator use (%)
|
72.3
|
Inhaled corticosteroid use (%)
|
68.1
|
Systemic corticosteroid use (%)
|
8.5
|